USFDA clears marketing of Zydus Cadila anti-hypertension drug
New Delhi: Zydus Cadila has received final approval from the US health regulator to market candesartan cilexetil tablets used for the treatment of hypertension.
The company has received the final nod from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 4 mg, 8 mg, 16 mg and 32 mg, Zydus Cadila said in a BSE filing.
The company will manufacture the drug at its formulations manufacturing facility in Moraiya, Ahmedabad.
It has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
The stock of the company's listed entity Cadila Healthcare was trading 7.38 per cent up at Rs 496.65 on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd